Literature DB >> 1522795

The limited role of the human interferon system response to respiratory syncytial virus challenge: analysis and comparison to influenza virus challenge.

N J Roberts1, J Hiscott, D J Signs.   

Abstract

The respiratory syncytial virus (RSV)-induced production of interferon (IFN) by human macrophages and mononuclear leukocytes (MNL) and the sensitivities of RSV to subtypes of IFN-alpha were examined and compared to IFN production induced by influenza virus. Influenza virus induced high titers of total IFN bioactivity, transcription of the IFN-alpha 1 and IFN-beta gene products and production of IFN-gamma. In contrast, RSV induced minimal or no detectable total IFN activity, and the absence of IFN bioactivity could not be attributed to inhibitors of IFN activity. There was no detectable transcription of IFN-alpha or IFN-beta gene products by the cells exposed to RSV. RSV-exposed MNL did produce small amounts of IFN-gamma, consistent with prior sensitization of the cell donors to the virus, but titers were substantially lower than those induced by influenza virus. RSV showed minimal but equivalent susceptibility to several subtypes of IFN-alpha. The data raise the possibility that the IFN system has a limited direct role in early host defense against RSV infection, but results should not be extrapolated directly to in vivo events.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1522795     DOI: 10.1016/0882-4010(92)90003-7

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  8 in total

1.  Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression.

Authors:  Brian D Rudd; Ezra Burstein; Colin S Duckett; Xiaoxia Li; Nicholas W Lukacs
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Respiratory syncytial virus induces interleukin-10 by human alveolar macrophages. Suppression of early cytokine production and implications for incomplete immunity.

Authors:  J R Panuska; R Merolla; N A Rebert; S P Hoffmann; P Tsivitse; N M Cirino; R H Silverman; J A Rankin
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

3.  Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins.

Authors:  Jean-Francois Valarcher; Julie Furze; Sara Wyld; Roy Cook; Karl-Klaus Conzelmann; Geraldine Taylor
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo.

Authors:  Nancy A Jewell; Negin Vaghefi; Sara E Mertz; Parvis Akter; R Stokes Peebles; Lauren O Bakaletz; Russell K Durbin; Emilio Flaño; Joan E Durbin
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

5.  Induction of type I interferons and interferon-inducible Mx genes during respiratory syncytial virus infection and reinfection in cotton rats.

Authors:  Lioubov M Pletneva; Otto Haller; David D Porter; Gregory A Prince; Jorge C G Blanco
Journal:  J Gen Virol       Date:  2008-01       Impact factor: 3.891

Review 6.  Human Type I Interferon Antiviral Effects in Respiratory and Reemerging Viral Infections.

Authors:  Patricio L Acosta; Alana B Byrne; Diego R Hijano; Laura B Talarico
Journal:  J Immunol Res       Date:  2020-05-08       Impact factor: 4.818

7.  Definition of erythroid cell-positive blood transcriptome phenotypes associated with severe respiratory syncytial virus infection.

Authors:  Darawan Rinchai; Matthew C Altman; Oceane Konza; Signe Hässler; Federica Martina; Mohammed Toufiq; Mathieu Garand; Basirudeen Syed Ahamed Kabeer; Karolina Palucka; Asuncion Mejias; Octavio Ramilo; Davide Bedognetti; Encarnita Mariotti-Ferrandiz; David Klatzmann; Damien Chaussabel
Journal:  Clin Transl Med       Date:  2020-12

8.  Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy.

Authors:  Diego R Hijano; David T Siefker; Bishwas Shrestha; Sridhar Jaligama; Luan D Vu; Heather Tillman; David Finkelstein; Jordy Saravia; Dahui You; Stephania A Cormier
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.